The prognosis of hepatocellular carcinoma after curative hepatectomy in young patients

Sang Yun Ha\textsuperscript{1,*}, Insuk Sohn\textsuperscript{2,*}, Soo Hyun Hwang\textsuperscript{1}, Jung Wook Yang\textsuperscript{1} and Cheol-Keun Park\textsuperscript{1}

\textsuperscript{1} Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
\textsuperscript{2} Biostatistics and Clinical Epidemiology Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea
* These authors have contributed to this paper equally

Correspondence to: Cheol-Keun Park, email: ckpark@skku.edu

Keywords: oncology, carcinogenesis, age, cell cycle, liver

Received: March 18, 2015 Accepted: May 26, 2015 Published: June 02, 2015

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Age at diagnosis is a reported prognostic factor in a variety of solid cancers. In hepatocellular carcinomas (HCCs), several previous studies focused on patient age, but demonstrated inconclusive results on prognosis of young patients. Clinical outcome may differ according to the balance between tumor’s own biologic behavior and underlying liver function thus explaining the inconclusive results in previous studies. In this study, we enrolled 282 patients who underwent curative hepatectomy for primary HCCs and had Child Pugh Class A, representing good liver function. Clinicopathologic features were compared between patients aged \leq 40 years (young age group) and those aged >40 years (old age group). Thirty-five patients (12.4\%) were classified as the young age group and showed larger tumor size (>5cm), higher Edmondson grade, more frequent intrahepatic metastasis and higher alpha-fetoprotein level (>200ng/mL) than old age group. Young age group showed shorter disease specific survival than the old age group. Symptomatic presentation without surveillance was more frequent in the young age group than old age group (45.7\% vs. 23.9\%). In gene expression profiling analysis, 69 differentially expressed genes between young and old age groups were generated and these genes were mostly associated with cell cycle or cell division. Mitotic rate was significantly higher in HCCs of young patients than those of old patients. In conclusion, HCCs in young patients have distinct clinicopathologic features. Poor prognosis in the young age group could be explained by late detection as well as their own aggressive tumor biology.

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common solid cancers and the second leading cause of cancer-related deaths globally, with only 7\% of 5 year survival rate [1]. The majority of HCC occurs in patients with underlying chronic liver disease [2] and surveillance for HCC detection in these risk groups is an important issue, especially the starting age of surveillance. Although, HCC usually occurs in middle aged and elderly patients, the peak age of incidence is different in various countries [3]. For example, the age at diagnosis in HCC patients is lower in hepatitis B- endemic country, such as Korea, than in hepatitis C- endemic areas, such as Western countries [3].

Age at diagnosis is a reported prognostic factor in a variety of solid cancers. Young patients with gastric or breast cancer have more aggressive disease and poorer prognosis than older ones [4, 5]. Conversely, young patients have a better clinical outcome than their elderly counterpart in thyroid papillary carcinoma and colorectal cancer [6, 7]. In HCC, the prognosis of young patients is controversial. Some authors reported better survival rates in young HCC patients, as compared to older patients [3,
8-10], while other studies showed opposite or arbitrary results [11-15]. Nevertheless, common clinicopathologic findings of young HCC patients have been reported in several studies, despite differences in clinical outcome. Young patients have more frequent HBV infection, less frequent HCV infection and higher alpha-fetoprotein (AFP) levels [3, 8-15]. They have relatively larger size and more advanced stage tumor than their elderly counterparts, while background liver function in young patients is relatively well preserved, as compared to older patients [3, 8, 10-14]. Clinical outcome may differ according to the balance between tumor’s own biologic behavior and liver function thus explaining the inconclusive results in previous studies.

We evaluated the prognosis of young patients among the 282 HCC patients with long term follow-up. We controlled for liver function by enrolling patients who underwent curative hepatectomy for primary HCCs and had Child Pugh Class A representing good liver function. Therefore, we determined the net prognostic effect of HCC in young patients.

RESULTS

Thirty-five of the 282 patients (12.4%) belonged to the young patient group. The comparison of clinicopathologic parameters between young and old age groups was summarized in Table 1. The frequency of young patients was higher in female than in male (34.3% vs. 14.6%, \( p = 0.004 \)). Tumor sized > 5cm was more frequently found in the young than old patient group (54.3% vs. 35.2%, \( p = 0.029 \)). The young patient group had more frequent high Edmondson grade (\( p < 0.001 \)), intrahepatic metastasis (\( p = 0.029 \)) and elevated serum AFP (\( p = 0.048 \)) than the old age group. Young patient group showed tendencies of higher HBV infection rate (88.6% vs. 74.9%) and lower HCV infection rate (0% vs. 9.7%) than the old patient group. The frequencies of background cirrhosis were similar between the 2 age groups (48.6% vs. 50.6%).

Young patient group showed shorter disease specific survival (DSS) (\( p = 0.032 \)) and a tendency of shorter disease free survival (DFS) (\( p = 0.218 \)), as compared to the old patient group (Figure 1). On multivariate analysis including covariables (mode of presentation, tumor size, Edmondson grade, microvascular invasion, major portal vein invasion, intrahepatic metastasis, serum albumin level, serum AFP level and etiology) with statistical significance in univariate analysis, patient age failed to demonstrate the statistical significance for both DFS and DSS (Table 2).

Factors for shorter disease-specific survival in young vs. old patients

We formulated 2 hypotheses for shorter DSS in young patients: 1. Late tumor detection at an advanced stage with conspicuous symptoms results from less
Table 1: The association between patient group by age and clinicopathologic parameters.

|                          | Total  | ≤40 years | > 40 years | p value |
|--------------------------|--------|-----------|------------|---------|
| **Gender**               |        |           |            |         |
| Female                   | 48 (17.0) | 12 (34.3) | 36 (14.6) | 0.004   |
| Male                     | 234 (83.0) | 23 (65.7) | 211 (85.4) |         |
| **Tumor size**           |        |           |            |         |
| ≤ 5cm                    | 176 (62.4) | 16 (45.7) | 160 (64.8) | 0.029   |
| > 5cm                    | 106 (37.6) | 19 (54.3) | 87 (35.2)  |         |
| **Edmondson grade**      |        |           |            |         |
| I                        | 32 (11.3)  | 1 (2.9) | 31 (12.6) | <0.001* |
| II                       | 226 (80.1) | 25 (71.4) | 201 (81.4) |         |
| III                      | 24 (8.5)  | 9 (25.7) | 15 (6.1)  |         |
| **Microvascular invasion**|     |           |            |         |
| (-)                      | 130 (46.1) | 12 (34.3) | 118 (47.8) | 0.134   |
| (+)                      | 152 (53.9) | 23 (65.7) | 129 (52.2) |         |
| **Major portal vein invasion** |   |           |            |         |
| (-)                      | 271 (96.1) | 32 (91.4) | 239 (96.8) | 0.144*  |
| (+)                      | 11 (3.9)  | 3 (8.6) | 8 (3.2)  |         |
| **Intrahepatic metastasis** |      |           |            |         |
| (-)                      | 218 (77.3) | 22 (62.9) | 196 (79.4) | 0.029   |
| (+)                      | 64 (22.7)  | 13 (37.1) | 51 (20.6)  |         |
| **Multicenteric occurrence** |    |           |            |         |
| (-)                      | 265 (94.0) | 34 (97.1) | 231 (93.5) | 0.704*  |
| (+)                      | 17 (6.0)  | 1 (2.9) | 16 (6.5)  |         |
| **AJCC T stage**         |        |           |            |         |
| 1                        | 122 (43.3) | 12 (34.3) | 110 (44.5) | 0.365*  |
| 2                        | 112 (39.7) | 14 (40.0) | 98 (39.7)  |         |
| 3                        | 42 (14.9)  | 8 (22.9) | 34 (13.8)  |         |
| 4                        | 6 (2.1)    | 1 (2.9) | 5 (2.0)  |         |
| **BCLC stage**           |        |           |            |         |
| 0-A                      | 162 (57.4) | 14 (40.0) | 148 (59.9) | 0.051*  |
| B                        | 107 (37.9) | 18 (51.4) | 89 (36.0)  |         |
| C                        | 13 (4.6)   | 3 (8.6) | 10 (4.0)  |         |
| **Albumin level, g/dL**  |        |           |            |         |
| >3.5                     | 21 (7.4)  | 4 (11.4) | 17 (6.9)  | 0.310*  |
| ≤ 3                      | 261 (92.6) | 31 (88.6) | 230 (93.1) |         |
| **AFP level, ng/mL**     |        |           |            |         |
| ≤200                     | 172 (61.0) | 16 (45.7) | 156 (63.2) | 0.048   |
| >200                     | 110 (39.0) | 19 (54.3) | 91 (36.8)  |         |
| Etiology                  | Non-viral | 4 (11.4) | 34 (13.8) | 0.203* |
|--------------------------|-----------|----------|-----------|--------|
| HBV                      | 216 (76.6)| 31 (88.6)| 185 (74.9)|        |
| HCV                      | 24 (8.5)  | 0 (0)    | 24 (9.7)  |        |
| HBV and HCV              | 4 (1.4)   | 0 (0)    | 4 (1.6)   |        |
| Liver cirrhosis          | (-)       | 140 (49.6)| 18 (51.4)| 122 (49.4)| 0.822 |
|                          | (+)       | 142 (50.4)| 17 (48.6)| 125 (50.6)|        |

* By Fisher’s exact test, otherwise by chi square test

**Table 2: Multivariate analysis for recurrence free survival and disease-specific survival.**

|                        | Disease Free Survival | Disease Specific Survival |
|------------------------|-----------------------|----------------------------|
|                        | HR        | 95% CI    | p value | HR   | 95% CI    | p value |
| Age                    |           |           |         |      |           |         |
| ≤40 years vs >40 years | 0.996     | 0.631-1.571 | 0.85   | 1.093 | 0.615-1.943 | 0.761 |
| Presentation           |           |           |         |      |           |         |
| Symptomatic vs others  | 1.166     | 0.816-1.667 | 0.399  | 1.35  | 0.851-2.141 | 0.203 |
| Tumor size             |           |           |         |      |           |         |
| >5cm vs ≤5cm           | 0.949     | 0.665-1.353 | 0.771  | 1.398 | 0.857-2.279 | 0.18  |
| Edmondson grade        |           |           |         |      |           |         |
| III vs I+II            | 1.403     | 0.830-2.372 | 0.206  | 1.336 | 0.712-2.509 | 0.367 |
| Microvascular invasion |           |           |         |      |           |         |
| yes vs no              | 1.335     | 0.921-1.933 | 0.127  | 1.5   | 0.84602.662 | 0.165 |
| Major portal vein      |           |           |         |      |           |         |
| invasion yes vs no     | 0.722     | 0.350-1.490 | 0.379  | 1.15  | 0.534-2.476 | 0.721 |
| Intrahepatic metastasis|           |           |         |      |           |         |
| yes vs no              | 3.693     | 2.426-5.623 | <0.001 | 3.444 | 2.041-5.809 | <0.001 |
| Albumin level, g/dL    |           |           |         |      |           |         |
| ≤3.5 vs >3.5           | 2.054     | 1.157-3.645 | 0.014  | 2.714 | 1.413-5.210 | 0.003 |
| AFP level, ng/mL       |           |           |         |      |           |         |
| >200 vs ≤200           | 1.338     | 0.97601.834 | 0.07   | 1.157 | 0.744-1.800 | 0.516 |
| Etiology\(^1\)         |           |           |         |      |           |         |
| Viral vs non-viral     | 1.655     | 0.996-2.750 | 0.052  |       |           |         |

HR, Hazard Ratio; CI, Confidence Interval

\(^1\)Etiology was not a significant factor in univariate analysis for disease specific survival and was not included in multivariate analysis.

**Table 3: Association between presentation mode and age group.**

| Presentation mode | Age | | |
|-------------------|-----|-----|
|                   | Total | ≤40 years | > 40 years | p value |
| Symptomatic       | 75 (26.6) | 16 (45.7) | 59 (23.9) | 0.021 |
| Surveillance      | 140 (49.6) | 14 (40.0) | 126 (51.0) | |
| Incidental        | 67 (23.8) | 5 (14.3) | 62 (25.1) |          |
Table 4: Functional annotation chart of 69 differentially expressed genes between young and old patient group.

| Category              | Term                                      | Count | %   | P value  | FDR    |
|-----------------------|-------------------------------------------|-------|-----|----------|--------|
| GOTERM_BP_FAT         | GO:0000278~mitotic cell cycle             | 15    | 25.0| 5.30E-11 | 7.55E-08|
| GOTERM_BP_FAT         | GO:0000279~M phase                       | 14    | 23.3| 1.70E-10 | 2.43E-07|
| SP_PIR_KEYWORDS       | mitosis                                  | 11    | 18.3| 1.99E-10 | 2.31E-07|
| GOTERM_BP_FAT         | GO:0022403~cell cycle phase              | 15    | 25.0| 2.34E-10 | 3.33E-07|
| SP_PIR_KEYWORDS       | cell division                            | 12    | 20.0| 4.13E-10 | 4.79E-07|
| GOTERM_BP_FAT         | GO:000280~nuclear division               | 12    | 20.0| 4.41E-10 | 6.29E-07|
| G0TERM_BP_FAT         | GO:0007067~mitosis                       | 12    | 20.0| 4.41E-10 | 6.29E-07|
| SP_PIR_KEYWORDS       | mitosis                                  | 11    | 18.3| 1.99E-10 | 2.31E-07|
| G0TERM_BP_FAT         | GO:000087~M phase of mitotic cell cycle  | 12    | 20.0| 5.34E-10 | 7.62E-07|
| G0TERM_BP_FAT         | GO:0048285~organelle fission             | 12    | 20.0| 6.76E-10 | 9.63E-07|
| G0TERM_BP_FAT         | GO:0051301~cell division                 | 12    | 20.0| 9.66E-09 | 1.38E-05|
| SP_PIR_KEYWORDS       | cell cycle                               | 13    | 21.7| 1.26E-08 | 1.45E-05|
| G0TERM_BP_FAT         | GO:007049~cell cycle                     | 17    | 28.3| 1.27E-08 | 1.82E-05|
| G0TERM_BP_FAT         | GO:0022402~cell cycle process            | 15    | 25.0| 1.30E-08 | 1.85E-05|
| G0TERM_CC_FAT         | GO:0044427~chromosomal part              | 9     | 15.0| 1.42E-05 | 0.0158605|
| G0TERM_CC_FAT         | GO:0005694~chromosome                    | 9     | 15.0| 5.00E-05 | 0.0557695|
| SP_PIR_KEYWORDS       | nucleus                                  | 28    | 46.7| 5.31E-05 | 0.0614677|
| G0TERM_CC_FAT         | GO:0005819~spindle                       | 6     | 10.0| 6.95E-05 | 0.0775141|
| SP_PIR_KEYWORDS       | microtubule                              | 7     | 11.7| 7.44E-05 | 0.0861766|
| G0TERM_CC_FAT         | GO:0005876~spindle microtubule           | 4     | 6.7 | 8.40E-05 | 0.0936886|

Table 5: Summary of previous studies regarding hepatocellular carcinoma in young patients.

| Author                | Year | Country | Total N | Cutoff (years) | Proportion of young patients | Diagnosis       | Treatment                      | Clinicopathologic findings                                                                 | Prognostic finding       |
|-----------------------|------|---------|---------|----------------|-----------------------------|----------------|--------------------------------|---------------------------------------------------------------------------------------------|--------------------------|
| Shimada et al. [14]   | 2013 | Japan   | 811     | 40             | 31 (3.8%)                   | Pathologically liver resection | more frequent HBV, less frequent HCV, higher AFP levels, more cases with a maximum tumor size of >=5cm, more microscopic tumor thrombus in portal vein, more intrahepatic metastasis | not significant in OS and | |
| Niederle et al. [9]   | 2012 | Germany | 1108    | 40             | 25 (2%)                     | Pathologically or clinically variable | less common underlying chronic liver disease in young age group, higher AFP levels, more frequent fibrolamellar carcinoma | better OS (p = 0.048) |
| Study            | Year | Country | Total | Age | Gender | Pathology | Surgery | Characteristics                                                                 | Outcome                                                                                          |
|------------------|------|---------|-------|-----|--------|-----------|---------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Takeishi et al.  | 2011 | Japan   | 610   | 40  | 13     | Pathologically | Curative | resection more frequent HBV, less frequent HCV, higher platelet count, higher AFP levels, larger size, poorly differentiated, more portal vein invasion, more advanced stage, shorter operative time | Tendency to better OS (p = 0.057) not significant in DFS (p = 0.762)                              |
| Chang et al.     | 2008 | Singapore | 638  | 40  | 55     | Pathologically or clinically | Variable | more frequent HBV, less frequent HCV, higher AFP levels, higher albumin, less cirrhosis, better child-Pugh class, more portal vein invasion, more advanced stage | Tendency to better OS (p = NS) better OS in stage I-III (p = 0.025)                                |
| Yamazaki et al.  | 2007 | Japan   | NA    | 40  | 20     | Pathologically or clinically | Variable | HBV 75%, Child Pugh Grade A 85%                                                | Eleven patients out of 20 died within 1 year                                                      |
| Cho et al.       | 2007 | Korea   | 320   | 30  | 71     | NA        | NA      | more frequent HBV, less frequent HCV, higher AFP levels, less cirrhosis, more advanced stage, more symptomatic patients | Poor survival than other age groups (p = 0.007) not significant after stage adjustment             |
| Chen et al.      | 2006 | Taiwan  | 11,312| 40  | 1229   | Pathologically or clinically | Variable | more frequent HBV, less frequent HCV, larger size                              | Paradoxical influence on survival worse 1 year survival (p < 0.001) better survival after 1 year (p < 0.001) |
| Kim et al.       | 2006 | Korea   | 4,234 | 30  | 38     | Pathologically or clinically | Variable | low frequency of smoking history, more frequent HBV, less frequent HCV, higher AFP levels, well-preserved liver function, larger tumor size, more advanced stage, more frequent application of surgical resection and chemotherapy as initial treatment | Better OS than age group (40-59) (p = 0.04) similar OS with age group (≥60) better OS than other age groups in TNM stage I and II (p = 0.04) |
The results of the several reports on the patient age in HCCs were summarized in Table 5. The prognosis of young HCC patients were inconclusive in previous studies [3, 8-15]. Among the 9 listed studies, better survival was reported in 4 studies, poorer survival in 3, and comparable or paradoxical influence on survival in 2. The criteria of young age was 40 years old in 7 studies, and 30 in 2 studies. The mode of diagnosis and modality for treatment were diverse. Nevertheless, common clinicopathologic findings in young patients have been suggested in many studies. More frequent HBV and less frequent HCV infection in young patients were reported in 7 of 9 studies, and higher AFP levels in 6 studies. Advanced tumor stage was found in 7 studies, while relatively good liver function was documented in 5 studies. These distinct clinicopathologic features were likewise observed in our study. The results collectively suggest that HCCs in young patients have their own biologic behavior.

The inconclusive effect on prognosis may be explained by the balance between aggressive tumor factor and good underlying liver function. We enrolled patients who were classified as a Child Pugh class A who underwent curative resection for primary HCCs. Therefore, we were able to control the effect of underlying liver function on patient survival. As a result, HCCs in young patients were associated with larger tumor size, higher Edmondson grade, more frequent intrahepatic metastasis and higher AFP level. These results were consistent with previous studies. The young age group showed shorter DSS than the old age group (p = 0.032), probably due to pure tumor effect with offsetting underlying liver function.

The causes of the aggressive phenotype of HCCs in young patients are not clear. We confirmed that symptomatic presentation without surveillance was more frequent in the young vs. old age group possibly due to late detection after progression to the advanced stage. This phenomenon was also documented in 2 previous studies by Cho et al. and Lam et al. [12, 13]. We identified the biologic difference of HCCs between young and old age groups, and compared gene expression profiles between the 2 groups after controlling for other confounding factors. As a result, DEGs were mostly associated with cell cycle or cell division. Further validation showed that the mitotic index was higher in the young patient group, as compared to old patient group. These results indicated that HCCs in young patients have their own aggressive behavior associated with increased cell division. A similar phenomenon was reported in a previous study by Geigl et al. on gene expression pattern according to aging using fibroblast cell lines and lymphocytes cultures from young and old patients [16]. They reported that a number of genes differentially expressed in aged cells were involved in both cell cycle and proliferation.

In fact, age was not an independent predictor of DFS and DSS in the multivariate analysis of this study, and poor outcome in young patients could be explained by advanced staging at the time of diagnosis. However, young patients showed shorter DSS than old patients in BCLC stage B-C group (Supplementary Figure 1B, p = 0.012) and a tendency of shorter DFS than old patients in BCLC 0-A group (Supplementary Figure 1C). These results suggest that poor outcome in young patients could not be fully originated from advanced staging of HCC at
the time of diagnosis, supporting the probable role of their own biologic features such as increased cell division.

American Association for the Study of Liver Diseases (AASLD) recommend HCC surveillance for all cirrhotic HBV patients, Asian male HBV patients older than 40 years and Asian female HBV patients older than 50 years [17]. In Korea, HCC surveillance is recommended in patients older than 40 years with cirrhosis or chronic HBV or HCV hepatitis by the Ministry of Health and Welfare and National Cancer Center. In this study, young HCC patients might have been subject to advanced stage on initial diagnosis because of less likelihood of being under surveillance, which led to late detection, and poor prognosis. For this reason, HCC surveillance begins at much younger ages in high risk group of patients in Korea. Whether this approach is cost effective or not remains to be determined and should be further investigated in the future study.

This study is a single center based retrospective study performed in Korea where HBV is the major etiology of HCC. Therefore, it has a limitation in the aspect of generalizability. Further studies are needed to validate major findings in this study.

In conclusion, HCCs in young patients have distinct clinicopathologic features. Poor prognosis in the young age group is possibly due to late detection as well as their own aggressive tumor biology.

**MATERIALS AND METHODS**

**Patient population and clinicopathologic information**

Initially, a total of 290 curative resected and pathologically confirmed primary HCCs at the Samsung Medical Center, Seoul, Korea from July 2000 to May 2006, were enrolled in the study. Eight cases with preoperative treatment such as trans-arterial chemoembolization, radiofrequency ablation or radiotherapy were excluded.

**Figure 2: Heatmap of differentially expressed genes in hepatocellular carcinoma of young and old patient groups.**

- **A.** 69 differentially expressed genes ($q$ value < 0.2)
- **B.** 18 cell cycle related genes.
and finally 282 patients were included in the study. Curative resection was defined as complete resection of all tumor nodules with clear microscopic resection margins and no residual tumors as indicated by a computed tomography scan 1 month after surgery.

We reviewed medical records of clinical parameters including age, gender, mode of presentation (surveillance, symptomatic, incidental), history of alcohol intake, and the results of laboratory test including serology for hepatitis virus A, B, C and D, AFP, and serum albumin. Surveillance was defined as a every 6-month screening with abdominal ultrasound and serum AFP for early detection of HCC in high risk patients with cirrhosis, HBsAg (+) or Anti-HCV Ab (+). Histopathologic features of HCCs such as histologic differentiation, microvascular invasion, major portal vein invasion, intrahepatic metastasis, multi-centric occurrence, and non-tumor liver pathology were reviewed by 2 pathologists (SYH and CKP). Histologic grading of HCCs were determined according to the criteria of Edmondson and Steiner [11]. Intrahepatic metastasis and multi-centric occurrence were determined according to the criteria of the Liver Cancer Study Group of Japan [12]. All patients were staged using the American Joint Committee on Cancer (AJCC) staging system [13] and Barcelona Clinic Liver Cancer (BCLC) staging classification [14]. The Institutional Review Board of Samsung Medical Center granted approval for this study.

The patients were followed-up every 3 months after surgery. The tumor recurrence was detected by 3 phase dynamic computed tomography scans or magnetic resonance imaging. The median follow-up period was 119.8 months (range 14.0-151.4 months) for survivors and the follow-up period for recurrence was at least 24 months. DFS was defined as the interval between the date of surgery and the date of HCC-related death. It was defined as: 1) the tumor occupying > 80% of the liver; 2) portal venous tumor thrombus proximal to the second bifurcation; 3) obstructive jaundice due to the tumor; 4) distant metastases; and 5) variceal hemorrhage with portal venous tumor thrombus proximal to the first bifurcation [18].

Comparison between patient groups according to patient age

We defined young patients as aged ≤ 40 years based on previous studies [8-11, 13-15]. Clinicopathologic parameters and survival in the young patient group were compared to those in patient group with age > 40 years.

Microarray data analysis

For comparison of gene expression profiling in young and old age group, we used our previously published microarray data of 240 cases [19]. A total of 240 cases were included in this study cohort. The expression data has been deposited in Gene Expression Omnibus (GSE 36376, http://www.ncbi.nlm.nih.gov/geo/). Multiple linear regression model was applied for adjusting confounding factors as follow: Edmondson grade, etiology, cirrhosis, AJCC T stage, albumin level, and AFP level. False discovery rate was applied for multiple correction. Differentially expressed genes (DEGs) selected by the criteria of \( p < 0.001 \) and \( q < 0.2 \), were imported into DAVID (the database for annotation, visualization, and integrated discovery) bioinformatics resources [20] to document biologic meaning associated with these gene lists.

Evaluation of mitotic rates

As a validation of gene expression profiling results, we compared the mitotic indices in young and old patient groups, using our previously reported data [21]. Multiple linear regression model was applied for adjusting confounding factors, similar to the microarray data analysis.

Statistical analysis

The association between age groups and clinicopathologic parameters was analyzed using the chi-square test, Fisher’s exact test or Cochran Armitage test. Survival analysis was performed using the Kaplan-Meier method, and the difference in survival rates was assessed by the log-rank test. The Cox proportional hazard regression model was used to assess the association between clinicopathologic factors and survival time. Significant prognostic factors identified by univariate analysis were entered into multivariate analysis. Proportional hazard assumption was checked by graphical method. We confirmed that variables in Cox proportional hazard model were constants that do not depend on time. All statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA) or R software (version 3.03). \( P \)-values < 0.05 were considered to be statistically significant.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

GRANT SUPPORT

This study was supported by Samsung Biomedical Research Institute Grant (#OTX0002001).
REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.

2. Yang JD, Nakamura I and Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011; 21: 35-43.

3. Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW and Rhee JC. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006; 21: 588-594.

4. Adami HO, Malker B, Holmberg L, Persson I and Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986; 315: 559-563.

5. Theuer CP, Kurosaki T, Taylor TH and Anton-Culver H. Unique features of gastric carcinoma in the young: a population-based analysis. Cancer. 1998; 83: 25-33.

6. Shaha AR, Shah JP and Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol. 1996; 3: 534-538.

7. Li Q, Cai G, Li D, Wang Y, Zhuo C and Cai S. Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. PLoS One. 2014; 9: e93756.

8. Chang PE, Ong WC, Lui HF and Tan CK. Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol. 2008; 43: 881-888.

9. Niederle IM, Worns MA, Koch S, Nguyen-Tat M, Duber C, Otto G, Schuchmann M, Galle PR and Weinmann A. Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort. J Clin Gastroenterol. 2012; 46: 775-778.

10. Takeishi K, Shirabe K, Muto J, Toshima T, Taketomi A and Maehara Y. Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg. 2011; 35: 1063-1071.

11. Chen CH, Chang TT, Cheng KS, Su WW, Yang SS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS and Lu SN. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int. 2006; 26: 766-773.

12. Cho SJ, Yoon JH, Hwang SS and Lee HS. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol. 2007; 22: 1226-1231.

13. Lam CM, Chan AO, Ho P, Ng IO, Lo CM, Liu CL, Poon RT and Fan ST. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening. Aliment Pharmacol Ther. 2004; 19: 771-777.

14. Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, Kamachi H and Taketomi A. Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma. World J Surg Oncol. 2013; 11: 52.

15. Yamazaki Y, Kakizaki S, Ohara N, Sato K, Takagi H, Arai H, Abe T, Katakai K, Kojima A, Matsuzaki Y and Mori M. Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis. Dig Dis Sci. 2007; 52: 1103-1107.

16. Geigl JB, Langer S, Barwisch S, Pfleghaar K, Lederer G and Speicher MR. Analysis of gene expression patterns and chromosomal changes associated with aging. Cancer Res. 2004; 64: 8550-8557.

17. Bruix J, Sherman M and American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.

18. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359: 1995-2004.

19. Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M, Xu J, Wang K, Shi S, Joh JW, Choi YL and Park CK. Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol. 2013; 20: 3747-3753.

20. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57.

21. Ha SY, Choi M, Lee T and Park CK. The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy. Cancer Res Treat. 2015.